Sanofi India Board Approves 70th AGM, Final Dividend & Appoints Siraj Chaudhry as Independent Director
Sanofi India's Board approved the 70th AGM on April 29, 2026. A final dividend of ₹48 per share was recommended for FY25. Mr. Siraj Azmat Chaudhry was appointed as an Additional and Independent Director for a five-year term from April 1, 2026.
The appointment of a new director and the declaration of a dividend are significant corporate actions that can impact shareholder value and corporate governance.
The appointment of an experienced director and the recommendation of a final dividend are positive developments for the company.
Sanofi India Limited's Board of Directors, in a meeting held on March 25, 2026, approved the convening of the Seventieth Annual General Meeting (70th AGM) on Wednesday, April 29, 2026, at 3:30 p.m. IST, to be conducted through Video Conferencing/Other Audio-Visual Means (VC/OAVM).
The Board also confirmed the recommendation of a Final Dividend of ₹48 per equity share of ₹10 each for the Financial Year ended December 31, 2025. This dividend is subject to shareholder approval at the upcoming 70th AGM. To facilitate this, the Register of Members and Share Transfer Books will be closed from April 23, 2026, to April 29, 2026, inclusive. The dividend will be paid to members registered on April 22, 2026.
Furthermore, the Board approved the appointment of Mr. Siraj Azmat Chaudhry (DIN: 00161853) as an Additional Director and Independent Director. This appointment is for a term of five consecutive years, commencing April 1, 2026, and concluding on March 31, 2031, subject to member approval at the 70th AGM. Mr. Chaudhry will hold office as an Additional Director until the date of the 70th AGM. He brings over 35 years of experience, including 20 years in leadership roles in the agriculture and food sectors, and has previously served as Chairman of Cargill India. He is not related to any existing directors and is not disqualified from directorship.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.